<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 13 Feb 2025 22:10:01 +0000</lastbuilddate>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Cardiovascular Disease in Anabolic Androgenic Steroid Users</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39945117/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: AAS use is associated with a substantially increased risk of cardiovascular disease in a large cohort with a long follow-up period.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 13. doi: 10.1161/CIRCULATIONAHA.124.071117. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Use of anabolic androgenic steroids (AASs) is associated with increased mortality, and case reports have suggested that some of these deaths are due to cardiovascular disease. However, the epidemiology of cardiovascular disease in AAS users is still relatively unexplored. This study aimed to measure the incidence of cardiovascular disease in male AAS users and to compare these rates with those of a cohort from the general population matched by age and sex.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Men sanctioned in an antidoping program for AAS use in Danish fitness centers between 2006 and 2018 were included and matched for age and sex with 50 times as many controls from the general Danish population. The cohort was followed until June 30, 2023. Using the nationwide registries, we obtained information on admissions, prescriptions, educational length, and occupational status for both the AAS users and controls. This study investigated the incidence of acute myocardial infarction, percutaneous coronary intervention, or coronary artery bypass graft, venous thromboembolism, ischemic stroke, arrhythmia, cardiomyopathy, heart failure, and cardiac arrest during the follow-up period.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During an average of 11 years of follow-up, AAS users (n=1189) demonstrated a significantly higher incidence of several cardiovascular events compared with controls (n=59 450). Correspondingly, AASs were associated with an increased risk of acute myocardial infarction (adjusted hazard ratio [aHR] 3.00 [95% CI, 1.67-5.39]), percutaneous coronary intervention or coronary artery bypass graft (aHR 2.95 [95% CI, 1.68-5.18]), venous thromboembolism (aHR 2.42 [95% CI, 1.54-3.80]), arrhythmias (aHR 2.26 [95% CI, 1.53-3.32]), cardiomyopathy (aHR 8.90 [95% CI, 4.99-15.88]), and heart failure (aHR 3.63 [95% CI, 2.01-6.55]). Due to the limited number of ischemic stroke and cardiac arrest cases among AAS users, these outcomes were not reportable.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: AAS use is associated with a substantially increased risk of cardiovascular disease in a large cohort with a long follow-up period.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39945117/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39945117</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071117>10.1161/CIRCULATIONAHA.124.071117</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39945117</guid>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Josefine Windfeld-Mathiasen</dc:creator>
<dc:creator>Ida M Heerfordt</dc:creator>
<dc:creator>Kim Peder Dalhoff</dc:creator>
<dc:creator>Jon Trærup Andersen</dc:creator>
<dc:creator>Michael Asger Andersen</dc:creator>
<dc:creator>Karl Sebastian Johansson</dc:creator>
<dc:creator>Tor Biering-Sørensen</dc:creator>
<dc:creator>Flemming Javier Olsen</dc:creator>
<dc:creator>Henrik Horwitz</dc:creator>
<dc:date>2025-02-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Disease in Anabolic Androgenic Steroid Users</dc:title>
<dc:identifier>pmid:39945117</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071117</dc:identifier>
</item>
<item>
<title>Evolution of Critical Care Cardiology: An Update on Structure, Care Delivery, Training, and Research Paradigms: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39945062/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>Critical care cardiology refers to the practice focus of and subspecialty training for the comprehensive management of life-threatening cardiovascular diseases and comorbid conditions that require advanced critical care in an intensive care unit. The development of coronary care units is often credited for a dramatic decline in mortality rates after acute myocardial infarction throughout the 1960s. As the underlying patient population became progressively sicker, changes in organizational...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 13. doi: 10.1161/CIR.0000000000001300. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Critical care cardiology refers to the practice focus of and subspecialty training for the comprehensive management of life-threatening cardiovascular diseases and comorbid conditions that require advanced critical care in an intensive care unit. The development of coronary care units is often credited for a dramatic decline in mortality rates after acute myocardial infarction throughout the 1960s. As the underlying patient population became progressively sicker, changes in organizational structure, staffing, care delivery, and training paradigms lagged. The coronary care unit gradually evolved from a focus on rapid resuscitation from ventricular arrhythmias in acute myocardial infarction into a comprehensive cardiac intensive care unit designed to care for the sickest patients with cardiovascular disease. Over the past decade, the cardiac intensive care unit has continued to transform with an aging population, increased clinical acuity, burgeoning cardiac and noncardiac comorbidities, technologic advances in cardiovascular interventions, and increased use of temporary mechanical circulatory support devices. Herein, we provide an update and contemporary expert perspective on the organizational structure, staffing, and care delivery in the cardiac intensive care unit; examine the challenges and opportunities present in the education and training of the next generation of physicians for critical care cardiology; and explore quality improvement initiatives and scientific investigation, including multicenter registry initiatives and randomized clinical trials, that may change clinical practice, care delivery, and the research landscape in this rapidly evolving discipline.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39945062/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39945062</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001300>10.1161/CIR.0000000000001300</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39945062</guid>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Shashank S Sinha</dc:creator>
<dc:creator>Bram J Geller</dc:creator>
<dc:creator>Jason N Katz</dc:creator>
<dc:creator>Cynthia Arslanian-Engoren</dc:creator>
<dc:creator>Christopher F Barnett</dc:creator>
<dc:creator>Erin A Bohula</dc:creator>
<dc:creator>Abdulla A Damluji</dc:creator>
<dc:creator>Venu Menon</dc:creator>
<dc:creator>Robert O Roswell</dc:creator>
<dc:creator>Saraschandra Vallabhajosyula</dc:creator>
<dc:creator>Amanda R Vest</dc:creator>
<dc:creator>Sean van Diepen</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>American Heart Association Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; and Council on Kidney in Cardiovascular Disease</dc:creator>
<dc:date>2025-02-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Evolution of Critical Care Cardiology: An Update on Structure, Care Delivery, Training, and Research Paradigms: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39945062</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001300</dc:identifier>
</item>
<item>
<title>Novel Directly Reprogrammed Smooth Muscle Cells Promote Vascular Regeneration as Microvascular Mural Cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39945059/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: A combination of myocardin and all-trans retinoic acid in defined culture conditions efficiently reprogrammed human fibroblasts into contractile and functional SMCs. The rSMCs were shown to be effective for vascular repair and contributed to neovascularization through mural cells and various paracrine effects. These human rSMCs could represent a novel source for cell-based therapy and research.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 13. doi: 10.1161/CIRCULATIONAHA.124.070217. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Although cell therapy has emerged as a promising approach to promote neovascularization, its effects are mostly limited to capillaries. To generate larger or stable vessels, layering of mural cells such as smooth muscle cells (SMCs) or pericytes is required. Recently, direct reprogramming approaches have been developed for generating SMCs. However, such reprogrammed SMCs lack genuine features of contractile SMCs, a native SMC phenotype; thus, their therapeutic and vessel-forming potential in vivo was not explored. Therefore, we aimed to directly reprogram human dermal fibroblasts toward contractile SMCs (rSMCs) and investigated their role for generating vascular mural cells in vivo and their therapeutic effects on ischemic disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We applied myocardin and all-<i>trans</i> retinoic acid with specific culture conditions to directly reprogram human dermal fibroblasts into rSMCs. We characterized their phenotype as contractile SMCs through quantitative reverse-transcriptase polymerase chain reaction, flow cytometry, and immunostaining. We then explored their contractility using a vasoconstrictor, carbachol, and through transmission electron microscope and bulk RNA sequencing. Next, we evaluated whether transplantation of rSMCs improves blood flow and induces vessel formation as mural cells in a mouse model of hind-limb ischemia with laser Doppler perfusion imaging and histological analysis. We also determined their paracrine effects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Our novel culture conditions using myocardin and all-<i>trans</i> retinoic acid efficiently reprogrammed human dermal fibroblasts into SMCs. These rSMCs displayed characteristics of contractile SMCs at the mRNA, protein, and cellular levels. Transplantation of rSMCs into ischemic mouse hind limbs enhanced blood flow recovery and vascular repair and improved limb salvage. Histological examination showed that vascular density was increased and the engrafted rSMCs were incorporated into the vascular wall as pericytes and vascular SMCs, thereby contributing to formation of stabler and larger microvessels. Quantitative reverse-transcriptase polymerase chain reaction analysis revealed that these transplanted rSMCs exerted pleiotropic effects, including angiogenic, arteriogenic, vessel-stabilizing, and tissue regenerative effects, on ischemic limbs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A combination of myocardin and all-<i>trans</i> retinoic acid in defined culture conditions efficiently reprogrammed human fibroblasts into contractile and functional SMCs. The rSMCs were shown to be effective for vascular repair and contributed to neovascularization through mural cells and various paracrine effects. These human rSMCs could represent a novel source for cell-based therapy and research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39945059/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39945059</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070217>10.1161/CIRCULATIONAHA.124.070217</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39945059</guid>
<pubDate>Thu, 13 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Cholomi Jung</dc:creator>
<dc:creator>Ji Woong Han</dc:creator>
<dc:creator>Shin-Jeong Lee</dc:creator>
<dc:creator>Kyung Hee Kim</dc:creator>
<dc:creator>Jee Eun Oh</dc:creator>
<dc:creator>Seongho Bae</dc:creator>
<dc:creator>Sangho Lee</dc:creator>
<dc:creator>Young-Jae Nam</dc:creator>
<dc:creator>Sangsung Kim</dc:creator>
<dc:creator>Chaewon Dang</dc:creator>
<dc:creator>Jaehyun Kim</dc:creator>
<dc:creator>Nakhyung Chu</dc:creator>
<dc:creator>Eun Jig Lee</dc:creator>
<dc:creator>Young-Sup Yoon</dc:creator>
<dc:date>2025-02-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Novel Directly Reprogrammed Smooth Muscle Cells Promote Vascular Regeneration as Microvascular Mural Cells</dc:title>
<dc:identifier>pmid:39945059</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070217</dc:identifier>
</item>
<item>
<title>Amara Yad Image: Cardiac Fibrous Skeleton-The Aortic Root, Tricuspid Valve, and the Membranous Septum</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39939045/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 18;85(6):655-656. doi: 10.1016/j.jacc.2024.12.022.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39939045/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39939045</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.022>10.1016/j.jacc.2024.12.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39939045</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Kalyanam Shivkumar</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Amara Yad Image: Cardiac Fibrous Skeleton-The Aortic Root, Tricuspid Valve, and the Membranous Septum</dc:title>
<dc:identifier>pmid:39939045</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.022</dc:identifier>
</item>
<item>
<title>Management of Coronary Stent Underexpansion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39939043/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>Coronary stent underexpansion is an important problem and limitation of percutaneous coronary intervention, adversely affecting both short- and long-term patient outcomes. Stent underexpansion occurs when a stent fails to expand adequately compared with the adjacent reference segment, resulting in inadequate luminal gain. Multiple studies suggest that stent underexpansion is associated with increased risks of in-stent restenosis, stent thrombosis, and myocardial infarction, resulting in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 18;85(6):625-644. doi: 10.1016/j.jacc.2024.12.009.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Coronary stent underexpansion is an important problem and limitation of percutaneous coronary intervention, adversely affecting both short- and long-term patient outcomes. Stent underexpansion occurs when a stent fails to expand adequately compared with the adjacent reference segment, resulting in inadequate luminal gain. Multiple studies suggest that stent underexpansion is associated with increased risks of in-stent restenosis, stent thrombosis, and myocardial infarction, resulting in recurrent symptoms, readmissions, repeat interventions, and increased mortality. Contributing factors for stent underexpansion include severe calcification, inadequate lesion preparation, suboptimal stent deployment, and preexisting in-stent restenosis. Calcific plaques, especially when present behind a previously implanted, underexpanded stent, pose a significant challenge for further stent optimization. These lesions are often resistant to high-pressure balloon dilatation and may require advanced techniques that carry increased risks of complications. Intravascular imaging modalities, such as intravascular ultrasound and optical coherence tomography, have emerged as essential tools in diagnosing and managing stent underexpansion. These techniques provide a more detailed evaluation of the vessel and previously implanted stent, enabling the clinician to understand the exact mechanism of stent failure, and assess plaque burden and morphology, which ultimately helps guide appropriate treatment strategies. Despite the clinical importance of stent underexpansion, there is currently no consensus on its optimal treatment, largely because of the absence of large prospective studies in this area. This comprehensive review aims to summarize the existing evidence, clinical experience, and treatment strategies for coronary stent underexpansion, with the goal of providing practical guidance to clinicians to help optimize percutaneous coronary intervention and patient outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39939043/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39939043</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.009>10.1016/j.jacc.2024.12.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39939043</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Primero Ng</dc:creator>
<dc:creator>Akiko Maehara</dc:creator>
<dc:creator>Ajay J Kirtane</dc:creator>
<dc:creator>Margaret McEntegart</dc:creator>
<dc:creator>Farouc A Jaffer</dc:creator>
<dc:creator>Darshan Doshi</dc:creator>
<dc:creator>Kevin J Croce</dc:creator>
<dc:creator>Brian A Bergmark</dc:creator>
<dc:creator>Jarrod D Frizzell</dc:creator>
<dc:creator>Emmanouil S Brilakis</dc:creator>
<dc:creator>Kathleen E Kearney</dc:creator>
<dc:creator>William L Lombardi</dc:creator>
<dc:creator>Lorenzo Azzalini</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Management of Coronary Stent Underexpansion</dc:title>
<dc:identifier>pmid:39939043</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.009</dc:identifier>
</item>
<item>
<title>Retraction of: Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39938556/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 13:ehaf081. doi: 10.1093/eurheartj/ehaf081. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39938556/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39938556</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf081>10.1093/eurheartj/ehaf081</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39938556</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Retraction of: Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk</dc:title>
<dc:identifier>pmid:39938556</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf081</dc:identifier>
</item>
<item>
<title>Distinct mismatch-repair complex genes set neuronal CAG-repeat expansion rate to drive selective pathogenesis in HD mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39938516/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>Huntington's disease (HD) modifiers include mismatch-repair (MMR) genes, but their connections to neuronal pathogenesis remain unclear. Here, we genetically tested 9 HD genome-wide association study (GWAS)/MMR genes in mutant Huntingtin (mHtt) mice with 140 inherited CAG repeats (Q140). Knockout (KO) of genes encoding a distinct MMR complex either strongly (Msh3 and Pms1) or moderately (Msh2 and Mlh1) rescues phenotypes with early onset in striatal medium-spiny neurons (MSNs) and late onset in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 8:S0092-8674(25)00100-X. doi: 10.1016/j.cell.2025.01.031. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Huntington's disease (HD) modifiers include mismatch-repair (MMR) genes, but their connections to neuronal pathogenesis remain unclear. Here, we genetically tested 9 HD genome-wide association study (GWAS)/MMR genes in mutant Huntingtin (mHtt) mice with 140 inherited CAG repeats (Q140). Knockout (KO) of genes encoding a distinct MMR complex either strongly (Msh3 and Pms1) or moderately (Msh2 and Mlh1) rescues phenotypes with early onset in striatal medium-spiny neurons (MSNs) and late onset in the cortical neurons: somatic CAG-repeat expansion, transcriptionopathy, and mHtt aggregation. Msh3 deficiency ameliorates open-chromatin dysregulation in Q140 neurons. Mechanistically, the fast linear rate of mHtt modal-CAG-repeat expansion in MSNs (8.8 repeats/month) is drastically reduced or stopped by MMR mutants. Msh3 or Pms1 deficiency prevents mHtt aggregation by keeping somatic MSN CAG length below 150. Importantly, Msh3 deficiency corrects synaptic, astrocytic, and locomotor defects in HD mice. Thus, Msh3 and Pms1 drive fast somatic mHtt CAG-expansion rates in HD-vulnerable neurons to elicit repeat-length/threshold-dependent, selective, and progressive pathogenesis in vivo.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39938516/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39938516</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.031>10.1016/j.cell.2025.01.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39938516</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Nan Wang</dc:creator>
<dc:creator>Shasha Zhang</dc:creator>
<dc:creator>Peter Langfelder</dc:creator>
<dc:creator>Lalini Ramanathan</dc:creator>
<dc:creator>Fuying Gao</dc:creator>
<dc:creator>Mary Plascencia</dc:creator>
<dc:creator>Raymond Vaca</dc:creator>
<dc:creator>Xiaofeng Gu</dc:creator>
<dc:creator>Linna Deng</dc:creator>
<dc:creator>Leonardo E Dionisio</dc:creator>
<dc:creator>Ha Vu</dc:creator>
<dc:creator>Emily Maciejewski</dc:creator>
<dc:creator>Jason Ernst</dc:creator>
<dc:creator>Brinda C Prasad</dc:creator>
<dc:creator>Thomas F Vogt</dc:creator>
<dc:creator>Steve Horvath</dc:creator>
<dc:creator>Jeffrey S Aaronson</dc:creator>
<dc:creator>Jim Rosinski</dc:creator>
<dc:creator>X William Yang</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Distinct mismatch-repair complex genes set neuronal CAG-repeat expansion rate to drive selective pathogenesis in HD mice</dc:title>
<dc:identifier>pmid:39938516</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.031</dc:identifier>
</item>
<item>
<title>Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39938515/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>Cancer is a systemic disease with complications beyond the primary tumor site. Among them, thrombosis is the second leading cause of death in patients with certain cancers (e.g., pancreatic ductal adenocarcinoma [PDAC]) and advanced-stage disease. Here, we demonstrate that pro-thrombotic small extracellular vesicles (sEVs) are secreted by C-X-C motif chemokine 13 (CXCL13)-reprogrammed interstitial macrophages in the non-metastatic lung microenvironment of multiple cancers, a niche that we define...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 10:S0092-8674(25)00094-7. doi: 10.1016/j.cell.2025.01.025. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cancer is a systemic disease with complications beyond the primary tumor site. Among them, thrombosis is the second leading cause of death in patients with certain cancers (e.g., pancreatic ductal adenocarcinoma [PDAC]) and advanced-stage disease. Here, we demonstrate that pro-thrombotic small extracellular vesicles (sEVs) are secreted by C-X-C motif chemokine 13 (CXCL13)-reprogrammed interstitial macrophages in the non-metastatic lung microenvironment of multiple cancers, a niche that we define as the pro-thrombotic niche (PTN). These sEVs package clustered integrin β<sub>2</sub> that dimerizes with integrin α<sub>X</sub> and interacts with platelet-bound glycoprotein (GP)Ib to induce platelet aggregation. Blocking integrin β<sub>2</sub> decreases both sEV-induced thrombosis and lung metastasis. Importantly, sEV-β<sub>2</sub> levels are elevated in the plasma of PDAC patients prior to thrombotic events compared with patients with no history of thrombosis. We show that lung PTN establishment is a systemic consequence of cancer progression and identify sEV-β<sub>2</sub> as a prognostic biomarker of thrombosis risk as well as a target to prevent thrombosis and metastasis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39938515/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39938515</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.025>10.1016/j.cell.2025.01.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39938515</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Serena Lucotti</dc:creator>
<dc:creator>Yusuke Ogitani</dc:creator>
<dc:creator>Candia M Kenific</dc:creator>
<dc:creator>Jacob Geri</dc:creator>
<dc:creator>Young Hun Kim</dc:creator>
<dc:creator>Jinghua Gu</dc:creator>
<dc:creator>Uthra Balaji</dc:creator>
<dc:creator>Linda Bojmar</dc:creator>
<dc:creator>Lee Shaashua</dc:creator>
<dc:creator>Yi Song</dc:creator>
<dc:creator>Michele Cioffi</dc:creator>
<dc:creator>Pernille Lauritzen</dc:creator>
<dc:creator>Oveen M Joseph</dc:creator>
<dc:creator>Tetsuhiko Asao</dc:creator>
<dc:creator>Paul M Grandgenett</dc:creator>
<dc:creator>Michael A Hollingsworth</dc:creator>
<dc:creator>Christopher Peralta</dc:creator>
<dc:creator>Alexandra E Pagano</dc:creator>
<dc:creator>Henrik Molina</dc:creator>
<dc:creator>Harry B Lengel</dc:creator>
<dc:creator>Elizabeth G Dunne</dc:creator>
<dc:creator>Xiaohong Jing</dc:creator>
<dc:creator>Madeleine Schmitter</dc:creator>
<dc:creator>Lucia Borriello</dc:creator>
<dc:creator>Thomas Miller</dc:creator>
<dc:creator>Haiying Zhang</dc:creator>
<dc:creator>Yevgeniy Romin</dc:creator>
<dc:creator>Katia Manova</dc:creator>
<dc:creator>Doru Paul</dc:creator>
<dc:creator>H Lawrence Remmel</dc:creator>
<dc:creator>Eileen M O'Reilly</dc:creator>
<dc:creator>William R Jarnagin</dc:creator>
<dc:creator>David Kelsen</dc:creator>
<dc:creator>Sharon M Castellino</dc:creator>
<dc:creator>Lisa Giulino-Roth</dc:creator>
<dc:creator>David R Jones</dc:creator>
<dc:creator>John S Condeelis</dc:creator>
<dc:creator>Virginia Pascual</dc:creator>
<dc:creator>James B Bussel</dc:creator>
<dc:creator>Nancy Boudreau</dc:creator>
<dc:creator>Irina Matei</dc:creator>
<dc:creator>David Entenberg</dc:creator>
<dc:creator>Jacqueline F Bromberg</dc:creator>
<dc:creator>Diane M Simeone</dc:creator>
<dc:creator>David Lyden</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2</dc:title>
<dc:identifier>pmid:39938515</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.025</dc:identifier>
</item>
<item>
<title>Neutrophil-derived vesicles control complement activation to facilitate inflammation resolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39938514/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>Although subsets with immunosuppressive properties exist, neutrophils are typically known for their pro-inflammatory role and pathogen clearance capabilities. Here, we reveal that neutrophils can paradoxically aid in resolving inflammation by actively producing anti-inflammatory extracellular vesicles. These large aging-neutrophil-derived vesicles (LAND-Vs) do not fit into classical vesicle categorizations due to their specific size, structure, or biogenesis pathway. They are protected from...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 3:S0092-8674(25)00050-9. doi: 10.1016/j.cell.2025.01.021. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Although subsets with immunosuppressive properties exist, neutrophils are typically known for their pro-inflammatory role and pathogen clearance capabilities. Here, we reveal that neutrophils can paradoxically aid in resolving inflammation by actively producing anti-inflammatory extracellular vesicles. These large aging-neutrophil-derived vesicles (LAND-Vs) do not fit into classical vesicle categorizations due to their specific size, structure, or biogenesis pathway. They are protected from efferocytotic clearance by phagocytes due to surface "do not eat me" signals and accumulate in the resolution phase of inflammation. CD55 on LAND-Vs exerts a robust, sustained anti-inflammatory effect by inhibiting complement 3 convertase, thereby reducing neutrophil recruitment and tissue damage. CD55<sup>+</sup> LAND-Vs originate in ordered lipid raft domains, where CD55 accumulates asymmetrically during neutrophil aging, and are subsequently formed through RhoA-dependent budding. Collectively, LAND-V emerges as a pivotal physiological immunomodulator and showcases functions that transcend the limited lifespan of neutrophils, offering a therapeutic target for inflammatory and infectious diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39938514/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39938514</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.021>10.1016/j.cell.2025.01.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39938514</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Alan Y Hsu</dc:creator>
<dc:creator>Qingxiang Huang</dc:creator>
<dc:creator>Xiong Pi</dc:creator>
<dc:creator>Jianing Fu</dc:creator>
<dc:creator>Krishnan Raghunathan</dc:creator>
<dc:creator>Laxman Ghimire</dc:creator>
<dc:creator>Arumugam Balasubramanian</dc:creator>
<dc:creator>Xuemei Xie</dc:creator>
<dc:creator>Hongbo Yu</dc:creator>
<dc:creator>Fabien Loison</dc:creator>
<dc:creator>Viraga Haridas</dc:creator>
<dc:creator>Jiali Zha</dc:creator>
<dc:creator>Fei Liu</dc:creator>
<dc:creator>Shin-Young Park</dc:creator>
<dc:creator>Kamal Bagale</dc:creator>
<dc:creator>Qian Ren</dc:creator>
<dc:creator>Yuping Fan</dc:creator>
<dc:creator>Yi Zheng</dc:creator>
<dc:creator>Jose A Cancelas</dc:creator>
<dc:creator>Li Chai</dc:creator>
<dc:creator>Sean R Stowell</dc:creator>
<dc:creator>Kanchao Chen</dc:creator>
<dc:creator>Rong Xu</dc:creator>
<dc:creator>Xiaoxue Wang</dc:creator>
<dc:creator>Yuanfu Xu</dc:creator>
<dc:creator>Lianghui Zhang</dc:creator>
<dc:creator>Tao Cheng</dc:creator>
<dc:creator>Fengxia Ma</dc:creator>
<dc:creator>Jay R Thiagarajah</dc:creator>
<dc:creator>Hao Wu</dc:creator>
<dc:creator>Sizhou Feng</dc:creator>
<dc:creator>Hongbo R Luo</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Neutrophil-derived vesicles control complement activation to facilitate inflammation resolution</dc:title>
<dc:identifier>pmid:39938514</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.021</dc:identifier>
</item>
<item>
<title>Patient Enrollment for Cardiovascular Clinical Trials in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937520/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 12. doi: 10.1001/jamacardio.2024.5537. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937520/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39937520</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5537>10.1001/jamacardio.2024.5537</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937520</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Muhammad Shahzeb Khan</dc:creator>
<dc:creator>Adeena Jamil</dc:creator>
<dc:creator>Muteia Shakoor</dc:creator>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>J Michael DiMaio</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Patient Enrollment for Cardiovascular Clinical Trials in the United States</dc:title>
<dc:identifier>pmid:39937520</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5537</dc:identifier>
</item>
<item>
<title>Intensive Blood Pressure Control in Older Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937510/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 12. doi: 10.1001/jamacardio.2024.5447. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39937510</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5447>10.1001/jamacardio.2024.5447</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937510</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Yuxian Huang</dc:creator>
<dc:creator>Xiangmin Tan</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Intensive Blood Pressure Control in Older Adults</dc:title>
<dc:identifier>pmid:39937510</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5447</dc:identifier>
</item>
<item>
<title>Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937508/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION AND RELEVANCE: In the OCEAN(a)-DOSE multicenter randomized clinical trial, olpasiran led to a significant and sustained reduction in OxPL-apoB but no significant effects on hs-CRP or hs-IL-6.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 12. doi: 10.1001/jamacardio.2024.5433. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Lipoprotein(a) (Lp[a]) is thought to be the major carrier of oxidized phospholipids (OxPL). OxPL are believed to be a potent driver of inflammation and atherosclerosis. Olpasiran, a small interfering RNA, blocks Lp(a) production by inducing degradation of apolipoprotein(a) messenger RNA. Olpasiran's effects on OxPL and systemic markers of inflammation are not well described.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the effects of olpasiran on OxPL, high-sensitivity interleukin 6 (hs-IL-6), and hs-C-reactive protein (hs-CRP) in the OCEAN(a)-DOSE randomized clinical trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: OCEAN(a)-DOSE was an international, multicenter, placebo-controlled, phase 2, dose-finding randomized clinical trial conducted between July 2020 and November 2022. A total of 281 patients with atherosclerotic cardiovascular disease and Lp(a) levels greater than 150 nmol/L were included.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Participants were randomized to receive 1 of 4 active subcutaneous doses of olpasiran vs placebo: (1) 10 mg, administered every 12 weeks (Q12W); (2) 75 mg, Q12W; (3) 225 mg, Q12W; or (4) 225 mg, administered every 24 weeks (Q24W). OxPL on apolipoprotein B (OxPL-apoB), hs-CRP, and hs-IL-6 were assessed at baseline, week 36, and week 48 in 272 patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was placebo-adjusted change in OxPL-apoB from baseline to week 36.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 272 participants, median (IQR) age was 62 years (56-69), and 86 participants (31.6%) were female. Baseline median (IQR) Lp(a) concentration was 260.3 nmol/L (198.1-352.4) and median (IQR) OxPL-apoB concentration was 26.5 nmol/L (19.7-33.9). The placebo-adjusted mean percentage change in OxPL-apoB from baseline to week 36 was -51.6% (95% CI, -64.9% to -38.2%) for the 10-mg Q12W dose, -89.7% (95% CI, -103.0% to -76.4%) for the 75-mg Q12W dose, -92.3% (95% CI, -105.6% to -78.9%) for the 225-mg Q12W dose, and -93.7% (95% CI, -107.1% to -80.3%) for the Q24W dose (P &lt; .001 for all). These effects were maintained to week 48 (-50.8%, -100.2%, -104.7%, and -85.8%, respectively; P &lt; .001 for all). There was a strong correlation between percentage reduction in Lp(a) and OxPL-apoB for patients treated with olpasiran (r = 0.79; P &lt; .001). Olpasiran did not significantly impact hs-CRP or hs-IL-6 compared with placebo to weeks 36 or 48 (P >; .05).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION AND RELEVANCE: In the OCEAN(a)-DOSE multicenter randomized clinical trial, olpasiran led to a significant and sustained reduction in OxPL-apoB but no significant effects on hs-CRP or hs-IL-6.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937508/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39937508</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5433>10.1001/jamacardio.2024.5433</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937508</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>J Antonio G López</dc:creator>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:creator>Seth J Baum</dc:creator>
<dc:creator>Elmer Stout</dc:creator>
<dc:creator>Norman E Lepor</dc:creator>
<dc:creator>Jeong-Gun Park</dc:creator>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:creator>Beat Knusel</dc:creator>
<dc:creator>Jingying Wang</dc:creator>
<dc:creator>Tomaz Wilmanski</dc:creator>
<dc:creator>Huei Wang</dc:creator>
<dc:creator>You Wu</dc:creator>
<dc:creator>Helina Kassahun</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Michelle L O'Donoghue</dc:creator>
<dc:creator>OCEAN(a)-DOSE Trial Investigators</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial</dc:title>
<dc:identifier>pmid:39937508</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5433</dc:identifier>
</item>
<item>
<title>Intensive Blood Pressure Control in Older Adults-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937507/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 12. doi: 10.1001/jamacardio.2024.5444. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937507/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39937507</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5444>10.1001/jamacardio.2024.5444</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937507</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Xiaofan Guo</dc:creator>
<dc:creator>Guozhe Sun</dc:creator>
<dc:creator>Yingxian Sun</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Intensive Blood Pressure Control in Older Adults-Reply</dc:title>
<dc:identifier>pmid:39937507</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5444</dc:identifier>
</item>
<item>
<title>Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis-The Time Has Come</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937467/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 12. doi: 10.1001/jamacardio.2024.5648. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937467/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39937467</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5648>10.1001/jamacardio.2024.5648</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937467</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Brian R Lindman</dc:creator>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:creator>Patricia A Pellikka</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis-The Time Has Come</dc:title>
<dc:identifier>pmid:39937467</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5648</dc:identifier>
</item>
<item>
<title>Arrhythmic Risk Stratification of Carriers of Filamin C Truncating Variants</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937464/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results suggest that the risk of SCD/MVA in phenotype-positive carriers of FLNCtv was high. A 5-variable predictive model derived from this cohort allows risk estimation and could support clinicians in the shared decision for prophylactic ICD implantation. External cohort validation is warranted.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 12. doi: 10.1001/jamacardio.2024.5543. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Filamin C truncating variants (FLNCtv) are a rare cause of cardiomyopathy with heterogeneous phenotypic presentations. Despite a high incidence of life-threatening ventricular arrhythmias and sudden cardiac death (SCD), reliable risk predictors to stratify carriers of FLNCtv are lacking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine factors predictive of SCD/major ventricular arrhythmias (MVA) in carriers of FLNCtv.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was an international, multicenter, retrospective cohort study conducted from February 2023 to June 2024. The Filamin C Registry Consortium included 19 referral centers for genetic cardiomyopathies worldwide. Participants included carriers of pathogenic or likely pathogenic FLNCtv. Phenotype negative was defined as the absence of any pathological findings detected by 12-lead electrocardiogram (ECG), Holter ECG monitoring, echocardiography, or cardiac magnetic resonance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Composite of SCD and MVA in carriers of FLNCtv.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of SCD and MVA, the last including aborted SCD, sustained ventricular tachycardia, and appropriate implantable cardioverter-defibrillator (ICD) interventions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 308 individuals (median [IQR] age, 45 [33-56] years; 160 male [52%]) with FLNCtv, 112 (36%) were probands, and 72 (23%) were phenotype negative. Median (IQR) left ventricular ejection fraction (LVEF) was 51% (38%-59%); 89 participants (34%) had LVEF less than 45%, and 50 (20%) had right ventricular dysfunction. During a median (IQR) follow-up of 34 (8-63) months, 57 individuals (19%) experienced SCD/MVA, with an annual incidence rate of 4 cases per 100 person-years (95% CI, 3-6). Incidence rates were higher in probands vs nonprobands and in phenotype-positive vs phenotype-negative individuals. A predictive model estimating SCD/MVA risk was derived from multivariable analysis, which included older age, male sex, previous syncope, nonsustained ventricular tachycardia, and LVEF with a time-dependent area under the curve (AUC) ranging between 0.76 (95% CI, 0.67-0.86) at 12 months and 0.78 (95% CI, 0.70-0.86) at 72 months. Notably, the association of LVEF with the SCD/MVA risk was not linear, showing significant lower risk for values of LVEF greater than 58%, and no increase for values less than 58%. Internal validation with bootstrapping confirmed good accuracy and calibration of the model. Results were consistent in subgroups analysis (ie, phenotype-positive carriers and phenotype-positive carriers without MVA at onset).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results suggest that the risk of SCD/MVA in phenotype-positive carriers of FLNCtv was high. A 5-variable predictive model derived from this cohort allows risk estimation and could support clinicians in the shared decision for prophylactic ICD implantation. External cohort validation is warranted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937464/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39937464</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5543>10.1001/jamacardio.2024.5543</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937464</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Filamin C Registry Consortium</dc:creator>
<dc:creator>Marta Gigli</dc:creator>
<dc:creator>Davide Stolfo</dc:creator>
<dc:creator>Giulia Barbati</dc:creator>
<dc:creator>Sharon Graw</dc:creator>
<dc:creator>Suet Nee Chen</dc:creator>
<dc:creator>Marco Merlo</dc:creator>
<dc:creator>Kristen Medo</dc:creator>
<dc:creator>Caterina Gregorio</dc:creator>
<dc:creator>Matteo Dal Ferro</dc:creator>
<dc:creator>Alessia Paldino</dc:creator>
<dc:creator>Maria Perotto</dc:creator>
<dc:creator>J Peter van Tintelen</dc:creator>
<dc:creator>Anneline S J M Te Riele</dc:creator>
<dc:creator>Annette F Baas</dc:creator>
<dc:creator>Arthur M Wilde</dc:creator>
<dc:creator>Ahmad S Amin</dc:creator>
<dc:creator>Arjan C Houweling</dc:creator>
<dc:creator>Perry Elliott</dc:creator>
<dc:creator>Douglas Cannie</dc:creator>
<dc:creator>Michelle Michels</dc:creator>
<dc:creator>Stephan A C Schoonvelde</dc:creator>
<dc:creator>Sanjay Prasad</dc:creator>
<dc:creator>Paz Upasana Tayal</dc:creator>
<dc:creator>Momina Yazdani</dc:creator>
<dc:creator>Deborah Morris-Rosendahl</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Eva Cabrera-Romero</dc:creator>
<dc:creator>Barbara Bauce</dc:creator>
<dc:creator>Kalliopi Pilichou</dc:creator>
<dc:creator>Diane Fatkin</dc:creator>
<dc:creator>Renee Johnson</dc:creator>
<dc:creator>Daniel P Judge</dc:creator>
<dc:creator>Kimberly L Foil</dc:creator>
<dc:creator>Stephane Heymans</dc:creator>
<dc:creator>Job A J Verdonschot</dc:creator>
<dc:creator>Sophie L V M Stroeks</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Purohit Anisha</dc:creator>
<dc:creator>Matthew O'Neill</dc:creator>
<dc:creator>M Benjamin Shoemaker</dc:creator>
<dc:creator>Dan M Roden</dc:creator>
<dc:creator>Hugh Calkins</dc:creator>
<dc:creator>Cynthia A James</dc:creator>
<dc:creator>Brittney Murray</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Euan A Ashley</dc:creator>
<dc:creator>Chloe Reuter</dc:creator>
<dc:creator>Massimo Imazio</dc:creator>
<dc:creator>Marco Canepa</dc:creator>
<dc:creator>Pietro Ameri</dc:creator>
<dc:creator>Jiangping Song</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Matthew R G Taylor</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Arrhythmic Risk Stratification of Carriers of Filamin C Truncating Variants</dc:title>
<dc:identifier>pmid:39937464</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5543</dc:identifier>
</item>
<item>
<title>Error in Abstract and Results</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937198/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 1;10(2):202. doi: 10.1001/jamacardio.2025.0009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937198/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39937198</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0009>10.1001/jamacardio.2025.0009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937198</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Abstract and Results</dc:title>
<dc:identifier>pmid:39937198</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0009</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937197/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 1;10(2):108. doi: 10.1001/jamacardio.2024.3409.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937197/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39937197</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3409>10.1001/jamacardio.2024.3409</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937197</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:39937197</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3409</dc:identifier>
</item>
<item>
<title>MYSTERY-HF - Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction - a Phase II Randomized Controlled Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937049/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 12. doi: 10.1161/CIRCULATIONAHA.125.074085. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937049/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39937049</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.074085>10.1161/CIRCULATIONAHA.125.074085</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937049</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Simon Braumann</dc:creator>
<dc:creator>Sascha Macherey-Meyer</dc:creator>
<dc:creator>Amin Polzin</dc:creator>
<dc:creator>Angelika Costard-Jäckle</dc:creator>
<dc:creator>Caroline Morbach</dc:creator>
<dc:creator>Bernhard Haring</dc:creator>
<dc:creator>Harald Lapp</dc:creator>
<dc:creator>Vincent Ten Cate</dc:creator>
<dc:creator>Alexander Gieswinkel</dc:creator>
<dc:creator>Jithmi Weliwitage</dc:creator>
<dc:creator>Martin Hellmich</dc:creator>
<dc:creator>Erik Michaëlsson</dc:creator>
<dc:creator>Karin Nelander</dc:creator>
<dc:creator>Nelli Ens-Jäger</dc:creator>
<dc:creator>Stephan Rosenkranz</dc:creator>
<dc:creator>Simon Gei C Df En</dc:creator>
<dc:creator>Norbert Frey</dc:creator>
<dc:creator>P Christian Schulze</dc:creator>
<dc:creator>Malin Aurell</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Stefan Frantz</dc:creator>
<dc:creator>Malte Kelm</dc:creator>
<dc:creator>Volker Rudolph</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Philipp Wild</dc:creator>
<dc:creator>Stephan Baldus</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>MYSTERY-HF - Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction - a Phase II Randomized Controlled Trial</dc:title>
<dc:identifier>pmid:39937049</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.074085</dc:identifier>
</item>
<item>
<title>Pregnancies in women after peri-partum cardiomyopathy: the global European Society of Cardiology EuroObservational Research Programme Peri-Partum Cardiomyopathy Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39936475/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Maternal morbidity and mortality rates were lower than anticipated. Baseline LVEF &lt;50% was not associated with an increased frequency of adverse maternal outcomes, and no further decline in LVEF was observed in this group. In contrast, women with SSPs and a baseline LVEF ≥50% experienced a decline in LVEF, potentially attributable to reduced use of heart failure pharmacotherapy during pregnancy and the post-partum period. Therapeutic termination was performed in approximately a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 12:ehaf006. doi: 10.1093/eurheartj/ehaf006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The risk of heart failure progression or mortality in patients with peri-partum cardiomyopathy (PPCM) during subsequent pregnancies (SSPs) is a significant concern for patients, their families, and healthcare providers. However, there is limited contemporary, prospective data on SSP outcomes in PPCM patients from diverse ethnic and sociodemographic groups. This study aimed to assess maternal and neonatal outcomes in PPCM patients undergoing SSPs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This is a sub-study on PPCM and SSPs of the global European Society of Cardiology PPCM Registry that recruited patients from 2012 to 2023. Maternal and neonatal outcomes were reported.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From 332 patients with PPCM, there were 98 SSPs among 73 women. Of these, 25 (26%) SSPs ended prematurely due to therapeutic termination (20/25), miscarriage (4/25), and stillbirth (1/25). The median follow-up from the end of the SSP was 198 days (inter-quartile range 160-240). Left ventricular ejection fraction (LVEF) was persistently reduced to &lt;50% prior to the SSP in 26% of patients, with only 6% having an LVEF &lt;40%. Patient characteristics were similar, irrespective of SSP baseline LVEF. Clinical worsening [composite of all-cause death, cardiovascular rehospitalization, or decline in LVEF ≥10% (percentage points) and to &lt;50%] occurred in 20% SSPs, with 2% all-cause maternal mortality. Signs/symptoms of heart failure and worsening of New York Heart Association class occurred in 26% and 22% of SSPs, respectively. At follow-up, the mean LVEF was 50% (±12%), and in 69% of SSPs, the LVEF was ≥50%. African women had similar outcome as the other ethnic groups. Pre-term delivery occurred in 24% of SSPs, 20% of babies were of low birth weight, and there was 3% all-cause neonatal mortality. Compared with women with SSP baseline LVEF &lt;50%, fewer women with LVEF ≥50% were on heart failure pharmacotherapies prior to the SSP, and in this group of women, there was a significant decline in LVEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Maternal morbidity and mortality rates were lower than anticipated. Baseline LVEF &lt;50% was not associated with an increased frequency of adverse maternal outcomes, and no further decline in LVEF was observed in this group. In contrast, women with SSPs and a baseline LVEF ≥50% experienced a decline in LVEF, potentially attributable to reduced use of heart failure pharmacotherapy during pregnancy and the post-partum period. Therapeutic termination was performed in approximately a fifth of cases. The findings suggest that reclassification of a SSP with persisting mild left ventricular impairment from modified World Health Organization (mWHO) Class IV (contraindicated) to mWHO III may be considered, while remaining under the care of an experienced medical team and with appropriate pharmacological management.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39936475/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39936475</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf006>10.1093/eurheartj/ehaf006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39936475</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Karen Sliwa</dc:creator>
<dc:creator>Alice Jackson</dc:creator>
<dc:creator>Charle Viljoen</dc:creator>
<dc:creator>Albertino Damasceno</dc:creator>
<dc:creator>Irina Mbanze</dc:creator>
<dc:creator>Hassan Al Farhan</dc:creator>
<dc:creator>Israa Fadhil Yaseen</dc:creator>
<dc:creator>Amam Mbakwem</dc:creator>
<dc:creator>Triwedya Indra Dewi</dc:creator>
<dc:creator>Zofia Dzielinska</dc:creator>
<dc:creator>Timur Abdullaev</dc:creator>
<dc:creator>Sorel Goland</dc:creator>
<dc:creator>Denise Hilfiker-Kleiner</dc:creator>
<dc:creator>Julia Hahnle</dc:creator>
<dc:creator>Carmen Basic</dc:creator>
<dc:creator>Alexandra Frogoudaki</dc:creator>
<dc:creator>Petar Seferovic</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pregnancies in women after peri-partum cardiomyopathy: the global European Society of Cardiology EuroObservational Research Programme Peri-Partum Cardiomyopathy Registry</dc:title>
<dc:identifier>pmid:39936475</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf006</dc:identifier>
</item>
<item>
<title>Mosaic loss of Y chromosome and mortality after coronary angiography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39935193/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: LOY represents an important independent risk factor for cardiovascular mortality in male patients with coronary artery disease. Targeting LOY may represent a sex-specific personalized medicine approach.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 12:ehaf035. doi: 10.1093/eurheartj/ehaf035. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Acquired somatic mutations emerged as important drivers of adverse cardiovascular disease outcomes. Recently, mosaic loss of Y chromosome (LOY) in haematopoietic cells was identified to induce diffuse cardiac fibrosis in male mice. The aim of the present study was to determine the association between LOY and cardiovascular mortality in patients undergoing coronary angiography.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: LOY was quantified in 1698 male participants of the LURIC study, who underwent coronary angiography, and its association with all-cause and cardiovascular mortality was determined. Furthermore, the interaction between LOY and inherited genetic susceptibility for cardiac fibrosis was assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The frequency of LOY steeply increased in male participants of LURIC at the age of 60 years. Loss of Y chromosome >; 17% was associated with significantly higher all-cause [hazard ratio (HR) 1.41, 95% confidence interval (CI) 1.09-1.82] and cardiovascular mortality (HR 1.49, 95% CI 1.09-2.03), which was driven by a higher risk for fatal myocardial infarction (HR 2.65, 95% CI 1.46-4.81). Loss of Y chromosome >; 17% was associated with a profibrotic and proinflammatory plasma protein expression profile as characterized by higher plasma levels of osteoprotegerin, matrix metalloproteinase-12, growth differentiation factor 15, heparin-binding EGF-like growth factor, and resistin. Genetic predisposition for lower myocardial fibrosis attenuated the association between LOY and cardiovascular mortality. Genome-wide methylation analyses identified differential methylation in 298 genes including ACTB, RPS5, WDR1, CD151, and ARAP1. Single-cell RNA sequencing further confirmed differential gene expression of 37 of these genes in LOY in peripheral blood mononuclear cells comprising a set of fibrosis-regulating genes including RPS5. RPS5 silencing in macrophages induced a paracrine induction of collagen expression in cardiac fibroblasts documenting a functional role in vitro.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: LOY represents an important independent risk factor for cardiovascular mortality in male patients with coronary artery disease. Targeting LOY may represent a sex-specific personalized medicine approach.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39935193/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39935193</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf035>10.1093/eurheartj/ehaf035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39935193</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Michael Weyrich</dc:creator>
<dc:creator>Stephen Zewinger</dc:creator>
<dc:creator>Tamim Sarakpi</dc:creator>
<dc:creator>Tina Rasper</dc:creator>
<dc:creator>Marcus E Kleber</dc:creator>
<dc:creator>Sebastian Cremer</dc:creator>
<dc:creator>Lukas Zanders</dc:creator>
<dc:creator>Fenja Fleck</dc:creator>
<dc:creator>Agneta Siegbahn</dc:creator>
<dc:creator>Lars Wallentin</dc:creator>
<dc:creator>Wesley Tyler Abplanalp</dc:creator>
<dc:creator>Linda Nerbas</dc:creator>
<dc:creator>Sandra Fay</dc:creator>
<dc:creator>Aaron L Eberle</dc:creator>
<dc:creator>Stefanie Dimmeler</dc:creator>
<dc:creator>Winfried März</dc:creator>
<dc:creator>Thimoteus Speer</dc:creator>
<dc:creator>Andreas M Zeiher</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mosaic loss of Y chromosome and mortality after coronary angiography</dc:title>
<dc:identifier>pmid:39935193</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf035</dc:identifier>
</item>
<item>
<title>Suspected de novo heart failure in outpatient care: the REVOLUTION HF study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39935142/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250213171000&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with suspected HF and elevated NT-proBNP had high mortality and morbidity in the weeks after presentation, and accrued substantial healthcare costs, highlighting an urgent need for prompt identification, evaluation, and treatment of HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 12:ehaf034. doi: 10.1093/eurheartj/ehaf034. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Ambulatory patients presenting with signs or symptoms of heart failure (HF) should undergo natriuretic peptide testing. Rates of death, HF hospitalization, and healthcare costs were examined in patients thus identified with suspected de novo HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This population-based study (REVOLUTION HF) encompassing two large healthcare regions in Sweden examined patients who presented to outpatient care for the first time between 1 January 2015 and 31 December 2020, who had a recorded sign (peripheral oedema) or symptom (dyspnoea) of HF, and whose N-terminal pro-B-type natriuretic peptide (NT-proBNP) measured >;300 ng/L within ±30 days of that sign or symptom. Characteristics, outcomes, healthcare patterns, and healthcare costs for these patients were followed for 1 year. Comparisons were made with matched controls without history of HF, its signs, its symptoms, or elevated NT-proBNP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 5942 patients (median age 78.7 years; 54% women) presented with suspected de novo HF. Within 1 year, 29% had received a HF diagnosis. Patients with suspected de novo HF had higher rates of all-cause death (11.7 vs. 6.5 events/100 person-years) and HF hospitalizations (12.5 vs. 2.2 events/100 person-years) than matched controls (n = 2048), with the highest event rates in the weeks after presentation. Rates were higher with higher NT-proBNP levels. Although some patients already used HF guideline-directed medical therapies for other indications, initiation of new medications was variable. Healthcare costs were higher in patients with suspected de novo HF than in matched controls, driven mostly by HF and chronic kidney disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with suspected HF and elevated NT-proBNP had high mortality and morbidity in the weeks after presentation, and accrued substantial healthcare costs, highlighting an urgent need for prompt identification, evaluation, and treatment of HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39935142/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250213171000&v=2.18.0.post9+e462414">39935142</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf034>10.1093/eurheartj/ehaf034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39935142</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Lisa Anderson</dc:creator>
<dc:creator>Antoni Bayes-Genis</dc:creator>
<dc:creator>Johan Bodegård</dc:creator>
<dc:creator>Katrina Mullin</dc:creator>
<dc:creator>Stefan Gustafsson</dc:creator>
<dc:creator>Giuseppe M C Rosano</dc:creator>
<dc:creator>Johan Sundström</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Suspected de novo heart failure in outpatient care: the REVOLUTION HF study</dc:title>
<dc:identifier>pmid:39935142</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf034</dc:identifier>
</item>





























</channel>
</rss>